[HTML][HTML] Pharmacogenetics aspects of oral anticoagulants therapy
FC Militaru, SC Vesa, TR Pop… - Journal of medicine and …, 2015 - ncbi.nlm.nih.gov
Abstract Rationale: Vitamin K antagonists (VKA), such as warfarin and acenocoumarol, are
widely used for the prevention and treatment of thromboembolic diseases and they are …
widely used for the prevention and treatment of thromboembolic diseases and they are …
[HTML][HTML] Oral anticoagulant therapy and bleeding events with vitamin K antagonists in patients with atrial fibrillation in a Hungarian county hospital
L Mark, G Dani, R Vendrey, G Paragh… - … medical journal of …, 2015 - ncbi.nlm.nih.gov
Background Vitamin K antagonists, despite their tight therapeutic spectrum and the fear of
bleeding complications, were long the most important drugs used in anticoagulant therapy …
bleeding complications, were long the most important drugs used in anticoagulant therapy …
Extrapolation of acenocoumarol pharmacogenetic algorithms
E Jiménez-Varo, M Cañadas-Garre… - Vascular …, 2015 - Elsevier
Introduction Acenocoumarol (ACN) has a narrow therapeutic range that is especially difficult
to control at the start of its administration. Various dosing pharmacogenetic-guided dosing …
to control at the start of its administration. Various dosing pharmacogenetic-guided dosing …
[PDF][PDF] Comparación de la adición de bajas dosis de vitamina K al tratamiento con acenocumarol frente al tratamiento tradicional con acenocumarol sobre la …
M Martínez Penella - 2015 - tdx.cat
El tratamiento de la anticoagulación oral con AVK es complicado debido a que las
propiedades farmacodinámicas, farmacocinéticas y su estrecho margen terapéutico, nos …
propiedades farmacodinámicas, farmacocinéticas y su estrecho margen terapéutico, nos …